Journal article

The Beyond Ageing Project Phase 2-a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial

Nicole L Cockayne, Shantel L Duffy, Rosalind Bonomally, Amelia English, Paul G Amminger, Andrew Mackinnon, Helen M Christensen, Sharon L Naismith, Ian B Hickie

TRIALS | BMC | Published : 2015

Abstract

BACKGROUND: Late-life depression is associated with high rates of morbidity, premature mortality, disability, functional decline, caregiver burden and increased health care costs. While clinical and public health approaches are focused on prevention or early intervention strategies, the ideal method of intervention remains unclear. No study has set out to evaluate the role of neurobiological agents in preventing depressive symptoms in older populations at risk of depression. METHODS/DESIGN: Subjects with previously reported sub-threshold depressive symptoms, aged 60 to 74 years, will be screened to participate in a single-centre, double-blind, randomised controlled trial with three parallel ..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

The trial is supported by the Bupa Health Foundation's Healthy Ageing initiative, along with the National Health and Medical Research Council of Australia, through a project grant awarded to the Brain & Mind Research Institute (1060397). For the purposes of the trial, EPAX 6000 TG/N (raw omega-3 fatty acid) is supplied in-kind by Pathway International Pty Ltd. The authors would like to thank Alexandra Aitken, Carmel Poyser and Janine Walker who assisted with development of trial procedures.